The GLP-1 conversation has become so total that it is easy to forget approved alternatives exist. They do — they are FDA-approved, they are oral, and they cost a fraction of what GLP-1 therapy costs.
They matter for three groups of patients. Those for whom GLP-1s are simply unaffordable, and for whom the realistic choice is not between semaglutide and a cheaper alternative but between an alternative and nothing. Those who could not tolerate GLP-1 side effects, particularly the gastrointestinal effects that cause many patients to discontinue during titration. And those for whom GLP-1s are clinically unsuitable because of contraindications.
Be clear about the trade-off going in: none of these medications matches GLP-1 weight loss. Qsymia, the strongest oral option, produces around 10% weight loss in clinical reporting, against 15% or more for injectable semaglutide and 20% or more for tirzepatide. That gap is real and should not be talked around.
What these medications offer instead is access: approved pharmacotherapy at $70 to $99 a month, taken as a tablet, through mechanisms that are entirely different from GLP-1 receptor agonism.
Why a Non-GLP-1 Option Might Be Right for You
Cost Is the Most Common Reason
Qsymia at $70 a month on a 90-day prescription and Contrave at $99 a month with free shipping cost roughly a tenth of brand-name GLP-1 list pricing. For a patient without insurance coverage, that is often the whole decision.
Different Mechanisms, Not Weaker Versions
Contrave acts on reward and craving pathways; Qsymia combines appetite suppression with an anticonvulsant that has weight effects. Neither is a diluted GLP-1 — they address different aspects of the problem, which is why they can work for patients GLP-1s did not.
No Injection Required
Both are oral. For patients with genuine needle aversion, an approved oral medication is a far better answer than a compounded oral GLP-1 drop or pill, which generally has weak or no supporting evidence.
Contraindication Lists Are Longer
Topiramate is associated with birth defects; phentermine is a controlled substance; naltrexone is contraindicated with opioid use; bupropion carries seizure risk. These medications require a genuine clinical assessment rather than a menu selection.
Generics Have Arrived
A generic version of Qsymia became available in May 2025 with reported costs from around $50, which puts effective approved pharmacotherapy within reach of almost any budget.
How We Evaluated These Options
✅ FDA Approval
Whether the medication is approved for chronic weight management, with full agency review of safety, efficacy and manufacturing.
📉 Documented Weight Loss
What the clinical evidence actually shows, stated plainly rather than compared favourably against nothing.
💵 Real Monthly Cost
The price a patient can actually access, including manufacturer programmes and generic availability.
⚕️ Contraindication Burden
How substantial the safety considerations are and how much clinical assessment they require.
💊 Route and Dosing
Oral versus injectable, and how many doses a day the maintenance regimen requires.
🔄 Mechanism Difference
Whether the medication offers a genuinely different mechanism, which is what makes it useful when GLP-1s have failed.
Qsymia
Qsymia combines phentermine, an appetite suppressant, with topiramate extended-release. Clinical reporting describes it as producing the highest weight loss of any oral weight-loss medication, at around 10% — below GLP-1 therapy, but a genuine clinical result from a once-daily capsule.
The manufacturer programme advertises $70 a month, applying to 90-day prescriptions only, with a note that 90-day prescriptions are not available in all states. A home delivery option is described at $89, and Costco members can pay $98 on a 30-day prescription. A generic became available in May 2025 with reported costs from around $50.
The reason it is not a universal answer is safety. Topiramate is associated with birth defects and must not be used in pregnancy; phentermine is a controlled substance with cardiovascular and psychiatric considerations. This requires a real clinical conversation, including explicit contraception planning for patients who could become pregnant.
✓ Why It Ranks Here:
- • Highest weight loss of any oral medication at around 10%
- • $70/month on 90-day prescriptions through the manufacturer programme
- • Generic available since May 2025 from around $50
- • FDA-approved for chronic weight management
- • Once-daily oral capsule, no injection
- • Roughly a tenth of brand-name GLP-1 list pricing
⚠ Considerations:
- • Topiramate is associated with birth defects — not for use in pregnancy
- • Phentermine is a controlled substance
- • $70 rate requires a 90-day prescription, not available in all states
- • Should not be stopped abruptly — requires tapering
Contrave
Contrave combines naltrexone and bupropion in an extended-release tablet, acting on reward and craving pathways rather than on gastric emptying and satiety hormones. For patients whose eating is driven more by craving than by hunger volume, that mechanistic difference is not a technicality.
The pricing is refreshingly plain: the manufacturer states all patients may pay $99 or less, with Contrave at $99 a month and free shipping through the CurAccess programme. Eligible commercially insured patients may pay $20 to $199 per 30-day fill depending on copay obligation.
That matters because retail pricing outside the programme has been reported around $742 to $836. The gap between knowing about CurAccess and not knowing about it is several hundred dollars a month — nobody should be paying retail here.
✓ Why It Ranks Here:
- • Flat $99/month with free shipping through the manufacturer programme
- • No dose-based price escalation
- • Targets reward and craving pathways, unlike any GLP-1
- • Some insured patients pay as little as $20 per fill
- • FDA-approved for chronic weight management
- • Oral extended-release tablet, no injection
⚠ Considerations:
- • Contraindicated with opioid use, including pain management
- • Bupropion carries seizure risk and neuropsychiatric warnings
- • Twice-daily dosing at maintenance
- • Less weight loss than GLP-1 therapy
Found
Found is one of the few telehealth platforms that treats non-GLP-1 medication as a genuine clinical pathway rather than a consolation prize. Its published pricing lists non-GLP-1 plan options starting at $49 per month alongside GLP-1s starting at $99.
The value of that structure is that a clinician can start you where the evidence and your circumstances point, and move you if it is not working, without you changing providers or starting over. For a patient who is not sure whether GLP-1 therapy is affordable or tolerable long-term, that flexibility has real worth.
Found also runs a Medicare GLP-1 Bridge pathway helping eligible Part D members access brand-name GLP-1s, and handles insurance paperwork — useful if your situation might change.
✓ Why It Ranks Here:
- • Non-GLP-1 plan options from $49/month
- • GLP-1 pathway available from $99/month on the same platform
- • Move between medication classes without changing provider
- • Insurance paperwork handled by the provider
- • Longer 3, 6 and 12-month plans reduce the monthly rate
⚠ Considerations:
- • Medication cost may be separate from plan pricing
- • Non-GLP-1 options produce less weight loss than GLP-1s
- • Confirm which specific medications are included at each tier
- • Plan pricing varies with commitment length
Nurx
Nurx offers bupropion and metformin for weight management through dedicated pathways at the same fee structure as its GLP-1 programme — a $79 one-time consultation fee plus a $79 monthly provider support fee, with medication billed separately.
Metformin in particular is worth knowing about. It is inexpensive, extremely well characterised after decades of use, and research on weight maintenance has suggested patients successfully treated with GLP-1 receptor agonists may be able to maintain weight loss using generic older-generation anti-obesity medications — a genuinely useful finding for anyone worried about long-term cost.
The Nurx fee structure is expensive for GLP-1s but reasonable for cheap generics, since the medication line is small. For a patient wanting a supervised metformin or bupropion pathway, this is a legitimate route.
✓ Why It Ranks Here:
- • Bupropion and metformin with dedicated clinical pathways
- • Same fee structure as the GLP-1 programme
- • Established platform with a broad medication range
- • Can move between medication classes without changing provider
- • Generic medications keep the medication line small
⚠ Considerations:
- • $79 consult plus $79/month before medication
- • Care fee is cash-pay only
- • Non-GLP-1 options produce less weight loss
- • Metformin is not FDA-approved for weight loss specifically
Non-GLP-1 Options Compared
| Medication | Mechanism | Weight Loss | Best Available Price | Key Contraindication |
|---|---|---|---|---|
| Qsymia | Appetite suppression + topiramate | Around 10% | $70/month (90-day Rx); generic from ~$50 | Pregnancy — birth defect risk |
| Contrave | Reward and craving pathways | Less than GLP-1 therapy | $99/month; $20 for some insured patients | Opioid use; seizure risk |
| Metformin | Insulin sensitivity and glucose metabolism | Modest | Generic, inexpensive | Kidney function considerations |
| Bupropion (alone) | Dopamine and norepinephrine reuptake | Modest | Generic, inexpensive | Seizure risk; eating disorder history |
| Semaglutide (comparison) | GLP-1 receptor agonist | 15%+ average | From $99/month compounded | Thyroid C-cell tumor boxed warning |
| Tirzepatide (comparison) | Dual GLP-1/GIP agonist | 20%+ average | From $99/month compounded | Thyroid C-cell tumor boxed warning |
Our Recommendation
Start by pricing GLP-1 therapy honestly, because the gap may be smaller than you think. Compounded semaglutide and tirzepatide are available from around $99 a month all-inclusive — comparable to Contrave’s $99 and only slightly above Qsymia’s $70. If cost was your only reason for looking at non-GLP-1 options, check the cheapest GLP-1 programmes first.
If GLP-1s are genuinely off the table — because of tolerability, contraindications, or a preference not to use a compounded product — then these options deserve serious consideration rather than being treated as leftovers. Qsymia is the most effective oral medication available and, with a generic since May 2025, among the cheapest. Contrave is the better fit if craving rather than portion size is what you are fighting.
Which one is appropriate is a clinical decision, not a price comparison. Topiramate and pregnancy, phentermine as a controlled substance, naltrexone and opioids, bupropion and seizure risk — these are substantial considerations, and the answer depends on your history rather than on which medication scores better in a table.
And there is one finding worth raising with your clinician if long-term cost worries you: research on weight maintenance has suggested that patients successfully treated with GLP-1 receptor agonists may be able to maintain their weight loss using generic older-generation anti-obesity medications. GLP-1 for the loss phase and a cheaper generic for maintenance is a strategy worth discussing.
Frequently Asked Questions
Are non-GLP-1 weight loss medications as effective?
No. Qsymia, the most effective oral option, produces around 10% weight loss in clinical reporting, against 15% or more for injectable semaglutide and 20% or more for tirzepatide. The gap is real. What non-GLP-1 medications offer is approved, affordable, oral pharmacotherapy through different mechanisms — which matters most when GLP-1s are unaffordable, untolerated or unsuitable.
Which is better, Qsymia or Contrave?
They work differently and suit different patients. Qsymia produces more weight loss, but topiramate is associated with birth defects and phentermine is a controlled substance. Contrave targets craving pathways and is contraindicated with opioid use and in patients at seizure risk. Which is appropriate depends on your medical history, not on which looks better in a comparison.
How much do non-GLP-1 weight loss medications cost?
Qsymia is $70 a month on 90-day prescriptions through the manufacturer programme, with a generic from around $50 since May 2025. Contrave is $99 a month with free shipping through CurAccess, or as little as $20 per fill for some eligible commercially insured patients. Both are roughly a tenth of brand-name GLP-1 list pricing.
Can I take a non-GLP-1 medication if GLP-1s made me sick?
That is one of the strongest reasons to consider them. Gastrointestinal side effects during titration are the most common reason patients discontinue GLP-1 therapy, and non-GLP-1 medications work through entirely different mechanisms — so a bad experience with semaglutide says nothing about how you would tolerate Contrave or Qsymia. Discuss it with your clinician.
What about metformin for weight loss?
Metformin is inexpensive, well characterised and available generically, though it is not FDA-approved for weight loss specifically. Research on weight maintenance has suggested patients successfully treated with GLP-1 receptor agonists may be able to maintain weight loss using generic older-generation anti-obesity medications, which makes it worth discussing for the maintenance phase in particular.
Can I use a non-GLP-1 medication to maintain weight loss after stopping a GLP-1?
This is worth raising with your clinician. Research on weight maintenance suggests it may be possible for some patients, and it addresses one of the biggest practical problems with GLP-1 therapy: the long-term cost of staying on it. It is a clinical decision, not something to attempt independently.
Are these medications available through telehealth?
Yes. Found lists non-GLP-1 plan options from $49 per month, and Nurx offers bupropion and metformin through dedicated pathways. Qsymia and Contrave both have manufacturer home delivery programmes. Note that some telehealth services can only issue 30-day prescriptions, which affects access to Qsymia’s $70 rate.
Do I still need to see a clinician?
Yes, and more meaningfully than for a GLP-1. These medications carry substantial contraindications — pregnancy and topiramate, opioid use and naltrexone, seizure history and bupropion, cardiovascular history and phentermine. This is not a category where selecting from a menu is appropriate.
Disclosure:
This guide is based on publicly available information including manufacturer-published pricing and programme terms for Qsymia and Contrave, FDA labelling information, clinical reporting on weight-loss medication efficacy, published research on weight maintenance using generic anti-obesity medications, and provider-published pricing, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews. Efficacy figures are drawn from clinical reporting and vary between individuals. Pricing depends on prescription length, state availability, pharmacy and programme eligibility — confirm your actual cost directly. All medications discussed carry contraindications requiring assessment by a clinician who knows your history. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This guide is for informational purposes only and is not medical advice. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.
Related Guides & Articles
Phentermine Review
The cheapest prescription option at around $37 a month, and its real limits.
Qsymia Review
The most effective oral weight-loss medication, its pricing and its contraindications.
Contrave Review
Targets cravings rather than satiety, at a flat $99 a month.
GLP-1 Alternatives Guide
The full landscape of options when GLP-1s are not the answer.
Cheapest GLP-1 Programs
If cost is the barrier, check what GLP-1 therapy actually costs first.
Compare All GLP-1 Providers
Read our independent reviews of every provider we cover
View All Reviews →